SEC Comment Letter for Jaguar Health, Inc. (JAGX) (CIK 0001585608) (JAGX) — Jul 28, 2025
Jaguar Health, Inc. (JAGX) (CIK 0001585608)
Date: July 28, 2025 · CIK: 0001585608 · Accession: 0000000000-25-007905
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288927
Letter
Re: Jaguar Health, Inc. Registration Statement on Form S-3 Filed July 24, 2025 File No. 333-288927 Dear Lisa A. Conte:
July 28, 2025
Lisa A. Conte Chief Executive Officer and President Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, California 94104
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Michael S. Lee, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 28, 2025 Lisa A. Conte Chief Executive Officer and President Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, California 94104 Re: Jaguar Health, Inc. Registration Statement on Form S-3 Filed July 24, 2025 File No. 333-288927 Dear Lisa A. Conte: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael S. Lee, Esq. </TEXT> </DOCUMENT>